Woodpecker3
2 weeks ago
$GLUE investors have been in what Cramer calls "the house of pain" for months. Many purchased this at $40,$50,$60,$70 per share. The company will be added to the long list of biotech failures once the inevitable FDA trial failure is confirmed.